The Quantellect read.As of Nov 19, 2026, 5 active firms cover Passage Bio Inc: 2 rate it Buy or better, 3 sit at Neutral, and 0 rate it Sell or worse, a neutral consensus. The target range is very wide, $7.00 to $23.00 (about 3.3x), which points to deep disagreement over how to value the company rather than near-term timing. The average target of $13.25 sits 230% above the current $4.01. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $-2.33 next quarter toward $-11.55 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS5 active firms
Neutral
Strong Buy00%
Buy240%
Neutral360%
Sell00%
Strong Sell00%
Based on 5 active firms as of Nov 19, 2026 (365-day activity window).
12-MONTH PRICE TARGET
$13.25
+230.4% upside
Average target across 4 active firms as of Nov 19, 2026 vs $4.01 current
Highest Target$23.00
Average Target$13.25
Lowest Target$7.00
Detailed analyst forecasts for PASG
Showing 1–5 of 5 named analysts shown · 5 active firms in the rating projection
As of Nov 19, 2026, 2 of 5 active firms rate PASG a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
PASG EPS & revenue forecast
EPS · NEXT QUARTER
$-2.33
Range $-4.06 – $-1.01 · 6 analysts · -43% YoY
Next period, 6 analysts expect Passage Bio Inc to earn $-2.33 a share (range $-4.06 – $-1.01), versus $-4.09 a year earlier. Full-year consensus is $-14.08, growing to $-11.55 the year after.
REVENUE · NEXT QUARTER
$0
Range $0 – $0 · 6 analysts
Revenue is expected to reach $0 (range $0 – $0). Full-year consensus is $0, rising to $0 next year.
Top analysts covering Passage Bio Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on PASG.
#1
Geulah Livshits
Chardan Capital · Rank #104
Buy
$21.00+423.7% to target
Overall win rate
43%
+ Follow
#2
Debjit Chattopadhyay
Guggenheim · Rank #248
Buy
$10.00+149.4% to target
Overall win rate
39%
+ Follow
#3
WI
Whitney Ijem
Canaccord Genuity · Rank #392
Buy
$23.00+473.6% to target
Overall win rate
35%
+ Follow
#4
Jay Olson
Oppenheimer · Rank #484
Buy
$15.00+274.1% to target
Overall win rate
31%
+ Follow
#5
YZ
Yun Zhong
Wedbush
Neutral
$8.00+99.5% to target
Coverage
—
+ Follow
PASG stock forecast FAQ
What is PASG's average 12-month price target?+
The 4 active firms with a live target average $13.25 for Passage Bio Inc over the next 12 months, ranging from a $23.00 high to a $7.00 low, as of Nov 19, 2026.
Is PASG stock a Buy, Sell or Neutral right now?+
The current consensus is Neutral. Of the 5 active firms as of Nov 19, 2026, 2 rate it Buy or Strong Buy, 3 rate it Neutral, and 0 rate it Sell or Strong Sell.
What are the highest and lowest price targets for PASG?+
The Street-high target is $23.00 (Canaccord Genuity), and the Street-low is $7.00 (Chardan Capital). The average of all 4 active-firm targets is $13.25.
How many active Wall Street firms cover PASG?+
5 active firms have a recognized rating on Passage Bio Inc as of Nov 19, 2026, and 4 active firms carry a live 12-month price target.
Who is the most accurate analyst covering PASG?+
Among analysts who currently cover PASG, Geulah Livshits of Chardan Capital has the strongest overall Quantellect track record (Rank #104). Their current call is Buy with a $21.00 target.
What is Passage Bio Inc's projected EPS for next quarter?+
The consensus estimate is $-2.33 per share (range $-4.06 – $-1.01) across 6 analysts. Full-year EPS is projected at $-14.08, rising to $-11.55 the following year.
How much revenue is Passage Bio Inc expected to report next quarter?+
Consensus revenue is $0 (range $0 – $0). Full-year revenue is projected at $0, growing to $0 next year.
Have analysts been upgrading or downgrading PASG lately?+
As of Nov 19, 2026, 2 of 5 active firms rate PASG a Buy (3 Neutral, 0 Sell). Historical months are month-end active-firm counts; the current month uses its actual as-of date.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their PASG calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.